BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1363223)

  • 1. Correlation of proliferative index (PCNA reactivity and Ki-67 reactivity) in primary breast carcinoma with hormone status, lymph node status, and disease-free survival.
    Magno WB; Hirschfield L; Bhuiya T; Harrison G; Mir R
    Conn Med; 1992 Dec; 56(12):667-9. PubMed ID: 1363223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proliferating cell nuclear antigen immunostaining in breast cancer and its relation to prognosis.
    Narita T; Funahashi H; Satoh Y; Takagi H
    Jpn J Clin Oncol; 1993 Feb; 23(1):20-5. PubMed ID: 8096256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical assessment of proliferation rate of breast carcinoma cells using Ki-67, MIB-1 and anti-PCNA monoclonal antibodies.
    Markiewski M; Domagała W
    Pol J Pathol; 1996; 47(4):189-94. PubMed ID: 9097711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer.
    Veronese SM; Maisano C; Scibilia J
    Anticancer Res; 1995; 15(6B):2717-22. PubMed ID: 8669852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal breast cancer: analysis of proliferative activity using a monoclonal antibody to proliferating cell nuclear antigen (PCNA) and its relationship to histological grade and prognosis.
    Lanzafame S; Magro G; Broggi B
    Pathologica; 1994 Apr; 86(2):150-6. PubMed ID: 7936757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinoma breast.
    Aziz SA; Pervez S; Khan SM; Kayani N; Nasir MI
    J Coll Physicians Surg Pak; 2005 Apr; 15(4):225-9. PubMed ID: 15857596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic impact in archival paraffin-embedded node-negative breast cancer.
    Siitonen SM; Kallioniemi OP; Isola JJ
    Am J Pathol; 1993 Apr; 142(4):1081-9. PubMed ID: 7682759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms.
    Goldblum JR; Shannon R; Kaldjian EP; Thiny M; Davenport R; Thompson N; Lloyd RV
    Mod Pathol; 1993 Nov; 6(6):663-8. PubMed ID: 7508113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of proliferative markers Ki-67 (MIB-1) and proliferating cell nuclear antigen (PC10) in transitional cell carcinoma of the renal pelvis.
    Cheville JC; Terrell RB; Cohen MB
    Mod Pathol; 1994 Sep; 7(7):794-800. PubMed ID: 7824516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PC-10 antibody to proliferating cell nuclear antigen (PCNA) is not related to prognosis in human breast carcinoma.
    Gasparini G; Meli S; Pozza F; Cazzavillan S; Bevilacqua P
    Growth Regul; 1992 Dec; 2(4):145-50. PubMed ID: 1363282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do proliferating cell nuclear antigen and MIB-1/Ki-67 have prognostic value in penile squamous cell carcinoma?
    Guimarães GC; Leal ML; Campos RS; Zequi Sde C; da Fonseca FP; da Cunha IW; Soares FA; Lopes A
    Urology; 2007 Jul; 70(1):137-42. PubMed ID: 17656224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of cell proliferation in breast cancer as determined by proliferating cell nuclear antigen (PCNA) immunostaining.
    Aaltomaa S; Lipponen P; Syrjänen K
    Anticancer Res; 1992; 12(4):1281-6. PubMed ID: 1380227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferating cell nuclear antigen immunostaining in breast carcinoma and its relationship to clinical and pathological variables.
    Agarwal S; Jain R; Rusia U; Gupta RL
    Indian J Pathol Microbiol; 1997 Jan; 40(1):11-6. PubMed ID: 9145605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proliferating-cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy: a comparison of PCNA and Ki-67.
    Taftachi R; Ayhan A; Ekici S; Ergen A; Ozen H
    BJU Int; 2005 Mar; 95(4):650-4. PubMed ID: 15705097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferative activity is a significant prognostic factor in male breast carcinoma.
    Pich A; Margaria E; Chiusa L
    Am J Pathol; 1994 Aug; 145(2):481-9. PubMed ID: 7519830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of immunohistochemical staining of proliferating cells in paraffin sections of breast carcinoma using antibodies to proliferating cell nuclear antigen and the Ki-67 antigen.
    Yu CC; Dublin EA; Camplejohn RS; Levison DA
    Anal Cell Pathol; 1995 Jul; 9(1):45-52. PubMed ID: 7577754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of relative proliferation rates of Wilms' tumor components using proliferating cell nuclear antigen and MIB-1 (Ki-67 equivalent antigen) immunostaining and assessment of mitotic index.
    Khine MM; Aung W; Sibbons PD; Howard CV; Clapham E; McGill F; Van Velzen D
    Lab Invest; 1994 Jan; 70(1):125-9. PubMed ID: 7905542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
    Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ
    Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
    Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
    Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.